4.3 Editorial Material

Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic

期刊

JOURNAL OF ADDICTION MEDICINE
卷 15, 期 6, 页码 448-451

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/ADM.0000000000000791

关键词

addiction; buprenorphine; COVID-19; substance use disorder; telemedicine

资金

  1. Massachusetts Department of Public Health, Bureau of Substance Addiction Services to develop Opioid Urgent Care Centers [1NTF230M03163724179]
  2. Gilead Sciences

向作者/读者索取更多资源

The Grayken Center for Addiction at Boston Medical Center swiftly innovated during the COVID-19 outbreak by offering telehealth services and maintaining focus on patients, especially those experiencing homelessness or with complex problems. Various measures were taken to ensure patient safety and continued access to treatment.
The Grayken Center for Addiction at Boston Medical Center includes programs across the care continuum for people with substance use disorders (SUDs), serving both inpatients and outpatients. These programs had to innovate quickly during the COVID-19 outbreak to maintain access to care. Federal and state regulatory flexibility allowed these programs to initiate treatment for people experiencing homelessness and maximize patient safety through physical distancing practices. Programs switched to telehealth with high levels of acceptability and patient retention. Some programs also maintained some face-to-face clinic visits to see patients with complex problems and to provide injectable medications. Text-messaging proved invaluable with adolescent and young adult clients, and a mobile-health outreach program was initiated to reach mother/child dyads affected by SUDs. A 24-hour hotline was implemented to support seamless access to treatment for hundreds released from incarceration early due to the pandemic. Boston Medical Center also launched the COVID Recuperation Unit to allow patients experiencing homelessness to recover from mild to moderate COVID-19 infection in an environment that took a harm-reduction approach to SUDs and provided rapid initiation of medication treatment. Many of these innovations increased access to treatment and retention of patients during the pandemic. Maintaining the revised regulations would allow flexibility to provide telehealth, extended prescriptions, and remote access to buprenorphine initiation to support and engage more patients with SUDs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据